WB
The startup develops non-opioid therapeutics that utilize small molecule compounds to target RNA splicing for treating rare congenital diseases and enhancing cancer immunotherapy. By promoting the secretion of endogenous opioids, the company addresses the need for effective treatments without the risks associated with traditional opioid medications.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops non-opioid therapeutics that utilize small molecule compounds to target RNA splicing for treating rare congenital diseases and enhancing cancer immunotherapy. By promoting the secretion of endogenous opioids, the company addresses the need for effective treatments without the risks associated with traditional opioid medications.